Interpretation of Risperidone Serum Concentrations
Your patient's total active moiety level of 45.4 ng/mL falls within the therapeutic range typically observed with standard dosing, and the roughly equal distribution between parent drug and metabolite suggests normal CYP2D6 metabolism. 1
Understanding the Active Moiety Concept
The clinical effect of risperidone results from the combined concentrations of risperidone plus 9-hydroxyrisperidone (the "active moiety"), as both compounds have similar pharmacological activity. 1, 2
Your patient's values show:
- Risperidone: 22.3 ng/mL
- 9-OH-risperidone: 23.1 ng/mL
- Total active moiety: 45.4 ng/mL (sum of both)
Therapeutic Range Context
In 90% of patients receiving the standard 6 mg/day dose, serum levels of the active moiety fall between 50-150 nmol/L (approximately 20-60 ng/mL), placing your patient's level of 45.4 ng/mL solidly within the expected therapeutic range. 3
The mean active moiety plasma level reported in clinical studies is approximately 41.6 ng/mL, making your patient's level slightly above average but well within normal limits. 4
Metabolizer Status Assessment
The metabolic ratio (risperidone/9-OH-risperidone) of approximately 0.97 (22.3/23.1) indicates your patient is likely a CYP2D6 extensive metabolizer, as the parent drug and metabolite are present in roughly equal proportions. 1, 2
Extensive metabolizers convert risperidone rapidly to 9-OH-risperidone, whereas poor metabolizers would show a much higher ratio with predominant parent drug accumulation. 1
CYP2D6 poor metabolizers (6-8% of Caucasians) typically show risperidone levels that far exceed 9-OH-risperidone levels, which is not the case here. 2
Clinical Implications for Efficacy
No clear concentration-response relationship exists for therapeutic efficacy within the therapeutic range—responders and non-responders often have similar active moiety levels. 5
Interestingly, some studies found that non-responders actually had significantly higher active moiety plasma levels (49.9 ng/mL) compared to responders (38.2 ng/mL), suggesting that simply increasing the dose may not improve outcomes. 4
Risk Assessment for Adverse Effects
Higher active moiety concentrations correlate with increased risk of extrapyramidal side effects (EPS), particularly parkinsonian symptoms. 5, 6
Patients developing clinically significant parkinsonian symptoms had significantly higher active moiety concentrations than those without parkinsonism. 5
Monitor specifically for dose-adjusted 9-OH-risperidone concentrations (C/D ratio), as elevated values (>4.78 ng/mL/mg) are associated with increased adverse drug reactions. 7
Monitoring Recommendations
Both risperidone and 9-OH-risperidone must be measured together, as risperidone alone may be undetectable (<0.1 ng/mL) in up to 18% of samples while 9-OH-risperidone remains present at therapeutic levels. 8
The large inter-individual variability (concentration-to-dose ratios varying by a factor of 20) means that dose adjustments should be guided by clinical response and tolerability rather than targeting specific plasma levels. 3, 8
Key Caveats
Age-related reductions in clearance occur, with the elimination half-life of 9-OH-risperidone extending to approximately 27 hours in elderly patients, requiring dose adjustments based on age and cognitive status. 6
Drug interactions with CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, duloxetine) can cause "phenoconversion," converting extensive metabolizers into functional poor metabolizers with markedly elevated risperidone levels. 9, 1
When co-administering CYP2D6 inhibitors, consider switching to antipsychotics with minimal CYP2D6 inhibition to avoid unpredictable concentration increases. 9